For tirzepatide, some animal data may be available, but it does not always predict what happens in human breastfeeding
Other Emerging Mechanisms Beyond multi-agonist drugs, researchers are exploring other novel pathways for treating obesity
High responder rates: At 60 mg, 80% achieved 5% and 45% achieved 7% weight loss (vs
She explains: When appetite decreases, overall food intake can drop, which may lead to nutrient gaps
When patients initiate treatment with GLP-1 receptor agonists, like semaglutide, or GIP and GLP-1 receptor agonists, like tirzepatide, they frequently ask physicians if they will need to continue the medication indefinitely in order to maintain weight loss